A Phase 2 interventional study of Etavopivat in Sickle Cell Disease, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S — 4 open to participants now, 5 under way, 3 of them phase 3. Anemia, Sickle Cell · Novo Nordisk A/S.
Among the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S, this one is the 11th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 5th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →4 of the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Australia, Belgium and 18 more countries
Ages 12+
Novo Nordisk A/S · Sites in United States, Canada, Egypt and 14 more countries
Ages 2+
Forma Therapeutics, Inc. · Sites in India, Nigeria, Oman
Ages 12–16
Forma Therapeutics, Inc. · Sites in Canada, France, Kenya and 4 more countries
Ages 6 mo–18 yrs
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 12 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2024.
This study's enrollment of 12 is below the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 95 across the 11 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
2 of the studies in Anemia, Sickle Cell by Novo Nordisk A/S that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06612268Phase 3Novo Nordisk A/SA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | 2027-08-27 |
| NCT05953584Forma Therapeutics, Inc.A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke | 2027-08-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.
This study is a pilot, open-label, single-arm study to evaluate the effect of etavopivat on cerebral hemodynamics, as measured by frequency domain near-infrared spectroscopy/diffuse correlation spectroscopy (FDNIRS/DCS) in participants 12 to 21 years of age with sickle cell disease (SCD). Cerebral blood flow (CBF), oxygen ejection fraction (OEF), and cerebral metabolic rate of oxygen (CMRO2) will be assessed FDNIRS/DCS in participants prior to, periodically throughout, and after 24 weeks of treatment with etavopivat. Approximately 12 participants will be enrolled.
The duration of study treatment will be 24 weeks. The study duration for individual participants may last up to 36 to 38 weeks and includes the Screening Period (up to 4 weeks before study treatment), the 24-week treatment period, a Safety Follow-up Visit at 4 weeks (+ 7 days) after the last dose of study drug, and an End of Study (EOS) visit approximately 8 weeks (± 7 days) after the last dose of study drug. A participant is considered to have completed the study if he or she has completed all phases of the study including the last visit or the last scheduled procedure shown in the Schedule of Events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any one of the following requiring a medical facility visit within 14 days prior to signing the form:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-arm, open-label
Drug: Etavopivat
The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
Also known as: FT-4202
Effect of etavopivat on cerebral blood flow (CBF)
Change in cerebral blood flow (CBF) assessments from baseline will be summarized with descriptive statistics by nominal study visit.
Time frame: 24 weeks
Effect of etavopivat on oxygen ejection fraction (OEF)
Change in OEF assessments from baseline will be summarized with descriptive statistics by nominal study visit.
Time frame: 24 weeks
Effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2)
Change in CMRO2 assessments from baseline will be summarized with descriptive statistics by nominal study visit.
Time frame: 24 weeks
Relationship between CBF and change in Hb levels
The change from baseline of CBF will be correlated to the corresponding post-baseline assessment for change in Hb.
Time frame: 24 weeks
Relationship between oxygen ejection fraction (OEF) and change in Hb levels
The change from baseline of OEF will be correlated to the corresponding post-baseline assessment for change in Hb.
Time frame: 24 weeks
Relationship between cerebral metabolic rate of oxygen (CMRO2) and change in Hb levels
The change from baseline of CMRO2 will be correlated to the corresponding post-baseline assessment for change in Hb.
Time frame: 24 weeks
Adverse events in participants with SCD
Maximum intensity of treatment emergent adverse events (TEAEs) will be summarized by system organ class and preferred term. The tabulation of deaths, serious TEAEs, serious drug-related TEAEs and TEAEs leading to study drug discontinuation will also be provided
Time frame: 24 weeks
Muscle hemodynamic effect of etavopivat on muscle blood flow
Change in muscle blood flow assessments from baseline will be summarized with descriptive statistics by nominal study visit.
Time frame: 24 weeks
Muscle hemodynamic effect of etavopivat on oxygen ejection fraction (OEF)
Change in OEF from baseline will be summarized with descriptive statistics by nominal study visit.
Time frame: 24 weeks
Muscle hemodynamic effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2)
Change in CMRO2 from baseline will be summarized with descriptive statistics by nominal study visit.
Time frame: 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Mar 2026, 24 months.
Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 24 months is below that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etavopivat